Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inhibikase Therapeutics, Inc.

1.66
-0.0400-2.35%
Post-market: 1.690.0300+1.81%17:23 EDT
Volume:278.05K
Turnover:478.24K
Market Cap:123.41M
PE:-2.02
High:1.86
Open:1.71
Low:1.66
Close:1.70
Loading ...

BRIEF-Inhibikase Therapeutics files for mixed shelf of up to $300 mln

Reuters
·
21 Jun

Inhibikase Therapeutics files $300M mixed securities shelf

TIPRANKS
·
21 Jun

Inhibikase Therapeutics : Sales Agreement Prospectus Covering Offering of up to $200 Mln Common Stock That May Be Issued From Time to Time

THOMSON REUTERS
·
21 Jun

Inhibikase Therapeutics Inc Files for Mixed Shelf of up to $300 Mln – SEC Filing

THOMSON REUTERS
·
21 Jun

Inhibikase Therapeutics Reports Q1 2025 Financial Results

TIPRANKS
·
23 May

Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating

TIPRANKS
·
16 May

Inhibikase Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Inhibikase Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
15 May

Inhibikase Therapeutics Reports $13.7M Net Loss in Q1 2025, EPS at $0.15

Reuters
·
15 May

Inhibikase Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
10 May

BRIEF-Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025

Reuters
·
26 Apr

Q32 Bio Inc - Iwicki Resigns to Focus on CEO Role at Inhibikase Therapeutics

THOMSON REUTERS
·
26 Apr

Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025

THOMSON REUTERS
·
26 Apr

BRIEF-Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO

Reuters
·
14 Apr

Inhibikase Names McIntyre Finance Chief as Lees-Rolfe Resigns

Dow Jones
·
14 Apr

Inhibikase Therapeutics announces appointment of McIntyre as CFO

TIPRANKS
·
14 Apr

Press Release: Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Dow Jones
·
14 Apr

Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses

Simply Wall St.
·
04 Apr

Inhibikase Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

Inhibikase Therapeutics FY 2024 GAAP EPS $(1.16) Misses $(0.90) Estimate

Benzinga
·
28 Mar